Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine Priming with R-GDP for R/R DLBCL (EPIC)
NCT03719989Phase 2Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2018
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine in diffuse large B-cell lymphoma (DLBCL), sponsored by Seoul National University Hospital. Primary endpoint: Objective Response Rate at 3 years. Status: unknown.
02
Drugs
azacitidine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03719989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719989.